4SC 2010 first 9 months revenue decreases from EUR1.

The ongoing Phase II SHELTER research is examining efficacy, basic safety and tolerability of resminostat in sufferers with advanced hepatocellular carcinoma as a monotherapy and in combination with the current standard for first-series treatment, sorafenib, in sorafenib-refractory patients. In 2010 September, preliminary promising interim data on the security, tolerability and efficacy was provided at the ‘2010 Visceral Medication’ symposium in Stuttgart, Germany.Most occupants reported that the presence of nighttime intensivists improved the quality of care as perceived by the resident, supplied support to residents, permitted appropriate resident autonomy, and improved the educational experience . Discussion In this single-center randomized trial of in-hospital nighttime intensivist staffing in an academic medical center in the United States, we found no evidence that staffing model, in comparison with nighttime telephone option of the daytime intensivist, had a significant effect on length of stay in a healthcare facility or ICU, ICU or in-hospital mortality, readmission to the ICU, or the probability of discharge to home.